{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:15:05Z","timestamp":1792440905026,"version":"4.5.0"},"reference-count":42,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,7,14]]},"published-print":{"date-parts":[[2025,10]]},"DOI":"10.2967\/jnumed.125.270170","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T17:20:10Z","timestamp":1754587210000},"page":"1622-1630","source":"Crossref","is-referenced-by-count":18,"title":["Lesion Absorbed Dose\u2013Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Milan","family":"Grkovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone S.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kuten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Shobeiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Augensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Humm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025100106250828000_66.10.1622.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025100106250828000_66.10.1622.2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol."},{"key":"2025100106250828000_66.10.1622.3","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1038\/s41598-017-04897-x","article-title":"Mutations in BRCA2 and taxane resistance in prostate cancer","volume":"7","author":"Nientiedt","year":"2017","journal-title":"Sci Rep."},{"key":"2025100106250828000_66.10.1622.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0764"},{"key":"2025100106250828000_66.10.1622.5","doi-asserted-by":"crossref","unstructured":"Teroerde M Nientiedt C Duensing A Hohenfellner M Stenzinger A Duensing S . Revisiting the role of p53 in prostate cancer. In: Bott SRJ Ng KL , eds. Prostate Cancer. Exon Publications; 2021.","DOI":"10.36255\/exonpublications.prostatecancer.p53.2021"},{"key":"2025100106250828000_66.10.1622.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01801-2"},{"key":"2025100106250828000_66.10.1622.7","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cancers13051102","article-title":"Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing","volume":"13","author":"Kabakov","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025100106250828000_66.10.1622.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2991"},{"key":"2025100106250828000_66.10.1622.9","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with \u03b2-emitting radionuclides","volume":"36","author":"O\u2019Donoghue","year":"1995","journal-title":"J Nucl Med."},{"key":"2025100106250828000_66.10.1622.10","first-page":"12S","article-title":"Tumor response to radiopharmaceutical therapies: the knowns and the unknowns","volume":"62(suppl3 3)","author":"Sgouros","year":"2021","journal-title":"J Nucl Med."},{"key":"2025100106250828000_66.10.1622.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267830"},{"key":"2025100106250828000_66.10.1622.12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40658-022-00501-y","article-title":"TriDFusion (3DF) image viewer","volume":"9","author":"Lafontaine","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2025100106250828000_66.10.1622.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263738"},{"key":"2025100106250828000_66.10.1622.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193706"},{"key":"2025100106250828000_66.10.1622.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023"},{"key":"2025100106250828000_66.10.1622.16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00259-024-06863-y","article-title":"The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE","volume":"52","author":"Maccauro","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025100106250828000_66.10.1622.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265987"},{"key":"2025100106250828000_66.10.1622.18","doi-asserted-by":"crossref","unstructured":"Tran-Gia J Cicone F Koole M . Rethinking dosimetry: a European perspective. J Nucl Med. May 22, 2025 [Epub ahead of print].","DOI":"10.2967\/jnumed.124.269378"},{"key":"2025100106250828000_66.10.1622.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148437"},{"key":"2025100106250828000_66.10.1622.20","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers13050962","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025100106250828000_66.10.1622.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268136"},{"key":"2025100106250828000_66.10.1622.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264363"},{"key":"2025100106250828000_66.10.1622.23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.annonc.2025.01.017","article-title":"Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG\/RTOG 0126 and SAKK 09\/10 trials","volume":"36","author":"Dal Pra","year":"2025","journal-title":"Ann Oncol."},{"key":"2025100106250828000_66.10.1622.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267730"},{"key":"2025100106250828000_66.10.1622.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025100106250828000_66.10.1622.26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/diagnostics11030428","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2025100106250828000_66.10.1622.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266991"},{"key":"2025100106250828000_66.10.1622.28","doi-asserted-by":"crossref","unstructured":"Moraitis A Prochnow A Poeppel TD . Tumor dose\u2013response relationship of [131I]MIBG therapy in patients with neural crest tumors by means of [124I]MIBG PET. J Nucl Med. March 13, 2025 [Epub ahead of print].","DOI":"10.2967\/jnumed.124.269377"},{"key":"2025100106250828000_66.10.1622.29","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.7150\/thno.99516","article-title":"Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics","volume":"14","author":"Hong","year":"2024","journal-title":"Theranostics."},{"key":"2025100106250828000_66.10.1622.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268457"},{"key":"2025100106250828000_66.10.1622.31","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","article-title":"Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer","volume":"50","author":"Mader","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025100106250828000_66.10.1622.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269447"},{"key":"2025100106250828000_66.10.1622.33","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/cancers16183120","article-title":"Model-informed radiopharmaceutical therapy optimization: a study on the impact of PBPK model parameters on physical, biological, and statistical measures in 177Lu-PSMA therapy","volume":"16","author":"Abdollahi","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2025100106250828000_66.10.1622.34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11864-025-01296-7","article-title":"Advances in PSMA-targeted radionuclide therapeutics","volume":"26","author":"Ruder","year":"2025","journal-title":"Curr Treat Options Oncol."},{"key":"2025100106250828000_66.10.1622.35","first-page":"538","article-title":"Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry","volume":"41","author":"O\u2019Donoghue","year":"2000","journal-title":"J Nucl Med."},{"key":"2025100106250828000_66.10.1622.36","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics."},{"key":"2025100106250828000_66.10.1622.37","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/RLU.0000000000005640","article-title":"225Ac-PSMA-617 augmentation after insufficient response under 177Lu-PSMA-617 radioligand therapy in mCRPC: evaluation of outcome and safety from a prospective registry (REALITY study)","volume":"50","author":"Rosar","year":"2025","journal-title":"Clin Nucl Med."},{"key":"2025100106250828000_66.10.1622.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267206"},{"key":"2025100106250828000_66.10.1622.39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2025100106250828000_66.10.1622.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264594"},{"key":"2025100106250828000_66.10.1622.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266268"},{"key":"2025100106250828000_66.10.1622.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268175"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:25:32Z","timestamp":1759325132000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.2967\/jnumed.125.270170"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270170","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}